Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and…
Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
July 22, 2025 12:45 ET | Source: F. Hoffmann-La Roche Ltd Participation…
